Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Dare Bioscience Inc (NQ: DARE )

1.310 USD -0.010 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 954,555
Open 1.300
Bid (Size) 1.330 (53)
Ask (Size) 1.340 (9)
Prev. Close 1.320
Today's Range 1.280 - 1.340
52wk Range 0.9100 - 3.850
Shares Outstanding 49,350,077
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Daré Bioscience to Present at 2021 BIO Digital
From GlobeNewswire News Releases
Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. Eastern Time 
From GlobeNewswire News Releases

Performance

YTD
N/A
N/A
1 Month
-0.76%
-0.76%
3 Month
-35.15%
-35.15%
6 Month
-6.43%
-6.43%
1 Year
+24.76%
+24.76%

More News

Read More
Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021
From GlobeNewswire News Releases
Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians
From GlobeNewswire News Releases
Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists
From GlobeNewswire News Releases
Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors
From GlobeNewswire News Releases
Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update
From GlobeNewswire News Releases
Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
From GlobeNewswire News Releases
Daré Bioscience to Host Full Year 2020 Financial Results and Company Update Conference Call and Webcast on March 30, 2021
From GlobeNewswire News Releases
Daré Bioscience Completes Recruitment in Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-Oral, Bio-identical Hormone Therapy for the Treatment of Vasomotor Sympt
From GlobeNewswire News Releases
Daré Bioscience to Participate in Upcoming Virtual Conferences
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.